Idioma:

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

Kim, Young Hak ; Hirabayashi, Masataka ; Kosaka, Shinji ; Nikaidoh, Junichi ; Yamamoto, Yasumichi ; Shimada, Masatoshi ; Toyazaki, Toshiya ; Nagai, Hiroki ; Sakamori, Yuichi ; Mishima, Michiaki

Cancer chemotherapy and pharmacology, 2013-06, Vol.71 (6), p.1445-1451 [Periódico revisado por pares]

Berlin/Heidelberg: Springer-Verlag

Texto completo disponível

Citações Citado por

Enviar para

Título:
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Autor: Kim, Young Hak ; Hirabayashi, Masataka ; Kosaka, Shinji ; Nikaidoh, Junichi ; Yamamoto, Yasumichi ; Shimada, Masatoshi ; Toyazaki, Toshiya ; Nagai, Hiroki ; Sakamori, Yuichi ; Mishima, Michiaki
Assuntos: Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cancer Research ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Disease Progression ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Glutamates - administration & dosage ; Glutamates - adverse effects ; Glutamates - therapeutic use ; Guanine - administration & dosage ; Guanine - adverse effects ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Humans ; Japan ; Kaplan-Meier Estimate ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Oncology ; Original Article ; Pemetrexed ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pneumology ; Prospective Studies ; Tumors ; Tumors of the respiratory system and mediastinum
É parte de: Cancer chemotherapy and pharmacology, 2013-06, Vol.71 (6), p.1445-1451
Descrição: Background Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). Subset analysis of a previous phase III study comparing pemetrexed with docetaxel in the second-line setting showed the superiority of pemetrexed in an elderly (≥70) population in both efficacy and toxicity. Patients and methods This was a single-arm phase II study of pemetrexed in elderly (≥75) Japanese patients with advanced non-squamous NSCLC. Patients received four cycles of pemetrexed (500 mg/m 2 ) every 3 weeks. The primary endpoint was the response rate, and secondary endpoints were safety and survival. Results Twenty-eight patients were enrolled between January 2010 and April 2012. The median age of the patients was 77 years (range 75–88). All but one patient had adenocarcinoma histology. The median number of chemotherapy cycles administered was 4 (range, 1–12). Seventeen (60 %) patients completed four cycles of chemotherapy. Partial response was achieved in 7 patients (response rate: 25 %) and stable disease in 11 patients (disease control rate: 64 %). Median progression-free survival and overall survival were 3.3 and 17.5 months, respectively. Grade 3/4 neutropenia and thrombocytopenia were observed in 8 patients (29 %) and 2 (7 %), respectively. Non-hematologic toxicities were generally mild, and there were no treatment-related deaths. Conclusions Although this study did not meet our primary endpoint, pemetrexed showed favorable antitumor activity with mild toxicity in elderly patients with non-squamous NSCLC. Further investigations of pemetrexed in this population are warranted (UMIN-CTR number, 000002452).
Editor: Berlin/Heidelberg: Springer-Verlag
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 8 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901

Kim, Young Hak ; Hirabayashi, Masataka ; Kosaka, Shinji ; Nikaidoh, Junichi ; Yamamoto, Yasumichi ; Shimada, Masatoshi ; Toyazaki, Toshiya ; Nagai, Hiroki ; Sakamori, Yuichi ; Mishima, Michiaki

Berlin/Heidelberg: Springer-Verlag

Buscando em bases de dados remotas. Favor aguardar.